{"symbol":"VRTX","fiscalQuarter":"Q1-2026","reportDate":"2026-05-04","reportTime":"AMC","status":"reported","company":{"name":"VERTEX PHARMACEUTICA","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/VRTX/earnings/Q1-2026","estimates":{"consensusEps":4.2923,"consensusRevenue":3001.06,"epsLow":3.67,"epsHigh":4.86,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on developing and commercializing innovative therapies for serious diseases. With a market cap of $108 billion, it plays a significant role in the health care sector, particularly in the treatment of cystic fibrosis and other genetic disorders.","keyMetrics":[{"name":"EPS","why":"Earnings per share is a key indicator of the company's profitability and financial health.","consensus":"$4.29"},{"name":"Revenue","why":"Revenue figures provide insight into the company's sales performance and market demand for its products.","consensus":"$3.0B"}],"lastQuarterRecap":{"summary":"In the last quarter (Q4-2025), Vertex reported an EPS of $5.03, exceeding estimates by 14.21%. The stock reacted positively, gaining 0.82% the following day.","promises":["Continued focus on expanding its pipeline of therapies.","Commitment to maintaining strong sales in existing products.","Plans to enhance research and development efforts."]},"wallStreetExpectations":{"summary":"Analysts expect Vertex to report strong earnings, with a consensus EPS of $4.29 and revenue of $3.0 billion. The company has a history of beating earnings expectations, which adds to investor optimism.","bullCase":"If Vertex exceeds EPS and revenue estimates, it could signal robust demand for its products and a strong pipeline, leading to a positive stock reaction.","bearCase":"If the company misses expectations or provides weak guidance, it could raise concerns about future growth and lead to a negative stock reaction."},"optionsSignal":{"impliedMove":"6.07%","context":"The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report."},"earningsTrackRecord":[{"quarter":"Q4-2025","epsSurprise":"+14.21%","reaction":"+0.82%"},{"quarter":"Q3-2025","epsSurprise":"+19.91%","reaction":"+0.10%"},{"quarter":"Q2-2025","epsSurprise":"+20.99%","reaction":"+2.19%"},{"quarter":"Q1-2025","epsSurprise":"+10.15%","reaction":"-0.19%"},{"quarter":"Q4-2024","epsSurprise":"+17.79%","reaction":"+0.14%"},{"quarter":"Q3-2024","epsSurprise":"+21.43%","reaction":"+0.36%"},{"quarter":"Q2-2024","epsSurprise":"-2.33%","reaction":"+2.03%"},{"quarter":"Q1-2024","epsSurprise":"+30.20%","reaction":"+0.35%"}],"pivotalQuestions":[{"question":"Will the EPS exceed $4.29 as expected?","whyItMatters":"A strong EPS could reinforce investor confidence in Vertex's profitability and growth potential."},{"question":"What guidance will management provide for future revenue?","whyItMatters":"Guidance on revenue will be crucial for assessing the company's growth trajectory and market position."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $4.50 or higher would confirm the bull case by showcasing strong earnings growth.","bearTrigger":"An EPS below $4.00 would confirm the bear case, indicating potential issues in performance.","context":"The market is debating Vertex's ability to maintain its growth momentum amidst competitive pressures and market dynamics."},"scenarioPlaybook":{"beatAndRaise":"If Vertex beats expectations, history suggests the stock could rise by around 0.54%, confirming strong demand for its products.","inLineCautious":"If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.","miss":"If Vertex misses expectations, history suggests a potential decline of around 2.03%, raising concerns about future growth."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating the potential for Vertex to exceed its earnings expectations due to strong sales in its existing therapies.","supportingPoints":["Vertex has consistently beaten EPS estimates in recent quarters, suggesting a trend of strong performance.","The options market is pricing a 6.07% move, indicating expectations for volatility that may not align with the company's historical stability."],"riskToConsensus":"If revenue growth exceeds $3.2 billion, it could challenge the current consensus and shift investor sentiment positively."},"whatToListenFor":["Updates on the sales performance of existing therapies.","Any new developments in the product pipeline.","Management's outlook on market conditions and competition.","Details on research and development initiatives.","Guidance for the upcoming quarters."],"metaDescription":"Vertex Pharmaceuticals (VRTX) reports Q1 2026 earnings May 4. Analysts expect $4.29 EPS on $3.0B revenue. Here's what to watch."},"postBrief":{"headline":"Vertex Pharmaceuticals Beats on EPS, Stock Up 1.4%","keyNumbers":[{"metric":"EPS","actual":"$4.47","expected":"$4.29","surprise":"+21.20%"},{"metric":"Revenue","actual":"N/A","expected":"$3.0B","surprise":"N/A"}],"managementCommentary":{"tone":"Unknown","keyQuotes":[],"summary":"No transcript is on record, so the analysis is based solely on numerical results."},"guidanceChanges":{"summary":"No forward guidance data is available for this quarter.","changes":[]},"whatItMeans":"Vertex Pharmaceuticals reported strong earnings with an EPS that exceeded expectations significantly, leading to a 1.4% increase in stock price. However, revenue figures were not disclosed, leaving some uncertainty. Investors may view the EPS beat positively, but the lack of revenue details and guidance could temper enthusiasm.","metaDescription":"Vertex Pharmaceuticals (VRTX) Q1 2026 earnings: EPS beat by 21.20%, revenue not disclosed. Stock up 1.4%. Full breakdown."}}